Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2083MR)

This product GTTS-WQ2083MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2083MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3138MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ1411MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ15902MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ15351MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ3622MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ7675MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ11149MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ11025MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-117
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW